Company: JACS-RI
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0001013762-25-000620
Chunk: 906

Company: Jackson Acquisition Co II
Filing Date: 2025-03-18
Form: 10-K
Item: Item 9
Chunk 906
---
incare Holdings, Inc. (Nasdaq: LNCR), a home healthcare services company with approximately $2.0 billion in annual revenues.
He was employed with Lincare for nearly 20 years and retired in December 2012 following the acquisition of Lincare by The Linde
Group AG in a transaction valued at $4.7 billion. Mr. Gabos was a member of the board of directors of MEDNAX, Inc. (NYSE: MD),
a physician practice management company, from 2002 until May 2022, where he served as Audit Committee Chairman and a member of the
Executive Committee of the board of directors. From 2013 to 2020, he was a member of the board of directors of Benefytt Technologies,
Inc. (Nasdaq: BFYT), a developer and administrator of individual health and insurance plans, and served as Chairman of its board of directors,
as well as Audit Committee Chairman, until its acquisition by Madison Dearborn Partners in August 2020. He was also a member of the
board of directors and Audit Committee Chairman of Life Line Screening Holdings, LLC from 2007 until its sale to Kinderhook Industries
in 2021, and PetVet Care Centers, Inc. until its sale to KKR & Co. in 2018. Prior to that, he was a merger and acquisition specialist
with Dean Witter Reynolds Inc. and for Coopers & Lybrand. Mr. Gabos holds a B.S. in Economics from The Wharton School of
the University of Pennsylvania. We believe that Mr. Gabos’ extensive management and consulting experience, as well as his previous
service on the boards of directors of public companies, qualify him to serve as a member of our board of directors.

Number, Terms of Office and Appointment of
Directors and Officers

Our board of directors consists
of five members. Prior to our initial business combination, holders of our Founder Shares will have the right to vote to appoint all of
our directors and remove members of the board of directors for any reason, and holders of our public shares will not have the right to
vote on the appointment of directors during such time. These provisions of our amended and restated memorandum and articles of association
may only be amended by a special resolution passed by a majority of at least 90% of our ordinary shares attending and voting at a general
meeting. Each of our directors will hold office for a three